MA56520A - Construction de l'interleukine 12 recombinante et ses utilisations - Google Patents

Construction de l'interleukine 12 recombinante et ses utilisations

Info

Publication number
MA56520A
MA56520A MA056520A MA56520A MA56520A MA 56520 A MA56520 A MA 56520A MA 056520 A MA056520 A MA 056520A MA 56520 A MA56520 A MA 56520A MA 56520 A MA56520 A MA 56520A
Authority
MA
Morocco
Prior art keywords
construction
recombinant interleukin
interleukin
recombinant
Prior art date
Application number
MA056520A
Other languages
English (en)
Inventor
Daniel Boden
Pooter Dorien De
Helen Horton
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MA56520A publication Critical patent/MA56520A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA056520A 2019-06-18 2020-06-18 Construction de l'interleukine 12 recombinante et ses utilisations MA56520A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19180939 2019-06-18

Publications (1)

Publication Number Publication Date
MA56520A true MA56520A (fr) 2022-04-27

Family

ID=67060253

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056520A MA56520A (fr) 2019-06-18 2020-06-18 Construction de l'interleukine 12 recombinante et ses utilisations

Country Status (4)

Country Link
EP (1) EP3986915A1 (fr)
CA (1) CA3141323A1 (fr)
MA (1) MA56520A (fr)
WO (1) WO2020255014A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019010222A2 (fr) 2017-07-03 2019-01-10 Torque Therapeutics, Inc. Polynucléotides codant pour des molécules de fusion immunostimulantes et leurs utilisations

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA92121A (fr) 1904-11-07 1905-03-14 William Waid Paddock Filtre a pression
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US6041252A (en) 1995-06-07 2000-03-21 Ichor Medical Systems Inc. Drug delivery system and method
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
CA2285056C (fr) 1997-04-03 2004-12-14 Iacob Mathiesen Methode pour l'introduction de substances pharmaceutiques et d'acides nucleiques dans le muscle squelettique
US5873849A (en) 1997-04-24 1999-02-23 Ichor Medical Systems, Inc. Electrodes and electrode arrays for generating electroporation inducing electrical fields
US6117660A (en) 1997-06-10 2000-09-12 Cytopulse Sciences, Inc. Method and apparatus for treating materials with electrical fields having varying orientations
JP2002507985A (ja) 1997-06-30 2002-03-12 ローヌ−プーラン・ロレ・エス・アー 横紋筋に核酸を導入する改良法およびその組合せ
EP2428249B1 (fr) 1998-07-13 2015-10-07 Inovio Pharmaceuticals, Inc. Thérapie génique ciblant la peau et les muscles par champ magnétique pulsé
US6319901B1 (en) 1998-10-15 2001-11-20 Ichor Medical Systems, Inc. Methods for prolonging cell membrane permeability
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US6912417B1 (en) 2002-04-05 2005-06-28 Ichor Medical Systmes, Inc. Method and apparatus for delivery of therapeutic agents
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
CA2532228C (fr) 2003-07-16 2017-02-14 Protiva Biotherapeutics, Inc. Arn interferant encapsule dans un lipide
NZ550342A (en) 2004-03-08 2010-06-25 Ichor Medical Systems Inc Improved apparatus for electrically mediated delivery of therapeutic agents
JP4796062B2 (ja) 2004-06-07 2011-10-19 プロチバ バイオセラピューティクス インコーポレイティッド 脂質封入干渉ｒｎａ
CN105457157B (zh) 2006-10-17 2020-04-14 因诺维奥制药公司 电穿孔装置及用其进行哺乳动物细胞电穿孔的方法
GB0901593D0 (en) 2009-01-30 2009-03-11 Touchlight Genetics Ltd Production of closed linear DNA
HRP20221522T1 (hr) 2010-07-06 2023-02-17 Glaxosmithkline Biologicals S.A. Čestice za dostavljanje nalik virionu za samo-replicirajuće rna molekule
GB201013153D0 (en) 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
JP2014525461A (ja) 2011-08-31 2014-09-29 ノバルティス アーゲー 免疫原をコードするｒｎａの送達のためのｐｅｇ化リポソーム
DK2817287T3 (da) 2012-02-24 2019-01-02 Arbutus Biopharma Corp Trialkyl kationisk lipid og metoder til anvendelse deraf
GB201502645D0 (en) 2015-02-17 2015-04-01 Touchlight Genetics Ltd Method
JP7072386B2 (ja) 2015-06-29 2022-05-20 アクイタス セラピューティクス インコーポレイテッド 核酸の送達のための脂質および脂質ナノ粒子製剤
AU2016334401A1 (en) * 2015-10-10 2018-04-26 Intrexon Corporation Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
US10166298B2 (en) 2015-10-28 2019-01-01 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
US9834510B2 (en) 2015-12-30 2017-12-05 Arcturus Therapeutics, Inc. Aromatic ionizable cationic lipid
US20190022247A1 (en) 2015-12-30 2019-01-24 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
EA202191975A2 (ru) 2016-03-28 2022-03-31 Айкор Медикэл Системс, Инк. Устройство для доставки терапевтических средств
US11357856B2 (en) 2017-04-13 2022-06-14 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
WO2018200943A1 (fr) 2017-04-28 2018-11-01 Acuitas Therapeutics, Inc. Nouveaux lipides carbonyles et formulations nanoparticulaires lipidiques pour l'administration d'acides nucléiques
EP3668833A1 (fr) 2017-08-16 2020-06-24 Acuitas Therapeutics, Inc. Lipides destinés à être utilisés dans des formulations nanoparticulaires lipidiques
US11524932B2 (en) 2017-08-17 2022-12-13 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US11542225B2 (en) 2017-08-17 2023-01-03 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
EP3668834A1 (fr) 2017-08-17 2020-06-24 Acuitas Therapeutics, Inc. Lipides destinés à être utilisés dans des formulations de nanoparticules lipidiques

Also Published As

Publication number Publication date
WO2020255014A1 (fr) 2020-12-24
EP3986915A1 (fr) 2022-04-27
CA3141323A1 (fr) 2020-12-24

Similar Documents

Publication Publication Date Title
MA52426A (fr) Conjugués d'il-15 et leurs utilisations
MA49033A (fr) Immunoconjugués d'un anticorps anti-pd-1 avec un il-2 mutant ou avec il-15
MA51288A (fr) Analogues d'incrétine et leurs utilisations
MA52773A (fr) Anticorps anti-cd3 et leurs utilisations
IL287273A (en) Recombinant polyclonal proteins and methods of using them
ZA202106880B (en) Anti-claudin 18.2 antibody and application thereof
MA49512A (fr) Protéines de liaison à l'antigène anti-papillomavirus humain et leurs méthodés d'utilisation
EP3902837A4 (fr) Anticorps monoclonal contre le récepteur alpha de l'interleukine-4 humaine et son utilisation
MA54947A (fr) Biomarqueurs de kinase 2 dépendant de la cycline et leurs utilisations
MA55080A (fr) Anticorps anti-mertk à affinité élevée et utilisations associées
MA54195A (fr) Conjugués d'interleukine 10 et leurs utilisations
MA53122A (fr) Variants d'anticorps cd38 et leurs utilisations
MX2020010951A (es) Anticuerpos anti-hla-g y utilizacion de los mismos.
MA49846A (fr) Anticorps qui se lient à l'egfr et à cmet
MA49398A (fr) Anticorps monoclonaux anti-igf-1r et utilisations de ceux-ci
EA202191806A1 (ru) Антитело против человеческого il-4ra и его применение
MA51705A (fr) Biomarqueur prédictif de la thérapie des lymphocytes infiltrant les tumeurs et ses utilisations
MA51147A (fr) Associations d'anticorps anti-c5 et utilisations associées
MA51230A (fr) Protéines f rsv stabilisées et leurs utilisations
MA54955A (fr) Anticorps anti-claudine 6 et leurs utilisations
MX2021012692A (es) Anticuerpos anti-mertk y sus metodos de uso.
IL277007A (en) Therapeutic ANTI-SPLA2-GIB antibodies and their uses
MA56520A (fr) Construction de l'interleukine 12 recombinante et ses utilisations
MA54469A (fr) Anticorps anti-il-27 et leurs utilisations
IL308382A (en) New anti-CD276 antibodies and their uses